<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; society</title>
	<atom:link href="http://www.tapanray.in/tag/society/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why Do Drug Companies Now Need More Focus On The 5th &#8220;P&#8221; Of Marketing?</title>
		<link>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing</link>
		<comments>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/#comments</comments>
		<pubDate>Mon, 07 Mar 2022 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[4 Ps]]></category>
		<category><![CDATA[5th P]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[driving]]></category>
		<category><![CDATA[Get Z]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[marketing-mix]]></category>
		<category><![CDATA[Millennial]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[purpose-driven marketing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[service]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10665</guid>
		<description><![CDATA[Astute marketers understand that over several decades, the much-known phraseology &#8211; ‘marketing mix’, has remained the bedrock of marketing a product or a service. The ‘Father of Modern Marketing’ - Philip Kotler defined this terminology as the &#8220;the set of controllable variables that &#8230; <a href="http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Create Purpose-Driven-Brands To Win Marketing Warfare In The New Reality</title>
		<link>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality</link>
		<comments>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/#comments</comments>
		<pubDate>Mon, 05 Oct 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[democratize]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Millennial]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[new reality]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[people]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[purpose-driven-brands]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[redefinition]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[warfare]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10286</guid>
		<description><![CDATA[As we navigate through the Covid days, the hope of somehow getting back to the pre-pandemic normal still lingers – notwithstanding a host of uncertainties in its way. The longing is driven by the hype of availability of scientifically proven, safe and &#8230; <a href="http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Acid Test For Excellence in Crisis Leadership</title>
		<link>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=acid-test-for-excellence-in-crisis-leadership</link>
		<comments>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/#comments</comments>
		<pubDate>Mon, 13 Apr 2020 00:07:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[21 day]]></category>
		<category><![CDATA[Acid]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Italy]]></category>
		<category><![CDATA[Juty]]></category>
		<category><![CDATA[leader]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[Mask]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[PPE]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[test]]></category>
		<category><![CDATA[turnaround]]></category>
		<category><![CDATA[United Staes]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9986</guid>
		<description><![CDATA[On April 12, 2020 – in the morning of the day 19 of the national lockdown, India’s total number of Coronavirus positive cases reached 8,504 with 289 deaths. The country&#8217;s trajectory is reportedly  steeper than most Asian peers, such as Singapore, Japan, and Indonesia. &#8230; <a href="http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why D&amp;I Is A Powerful Growth Driver For Pharma Industry</title>
		<link>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-di-is-a-powerful-growth-driver-for-pharma-industry</link>
		<comments>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/#comments</comments>
		<pubDate>Mon, 10 Jun 2019 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[empathetic]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[facets]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[two]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9578</guid>
		<description><![CDATA[‘Diverse India’ now needs an ‘inclusive society’, vowed the Prime Minister of India, after his massive electoral win on May 23, 2019. Many may consider a part of it as rhetoric, notwithstanding, as and when the government policy of Diversity and Inclusion &#8230; <a href="http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Pricing Pressure to Escalate Further?</title>
		<link>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-pricing-pressure-to-escalate-further</link>
		<comments>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/#comments</comments>
		<pubDate>Mon, 12 Feb 2018 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[Central Medical]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[escalate]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HPS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Niti Aayog]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Progressive India” report]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[“Healthy States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8849</guid>
		<description><![CDATA[On February 09, 2018, NITI Aayog released its “Healthy States, Progressive India” Report. The study ranked the States based on ‘health index’. Kerala, Punjab and Tamil Nadu featured as top three in terms of overall performance in 2015-16. However, the interstate variation &#8230; <a href="http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘The Memory Thief’ Still Eludes Grasp Of Pharma R&amp;D</title>
		<link>http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-memory-thief-still-eludes-grasp-of-pharma-rd</link>
		<comments>http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/#comments</comments>
		<pubDate>Mon, 01 Feb 2016 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ADEAR]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[brain]]></category>
		<category><![CDATA[bullet]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eludes]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[flickers]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[grasp]]></category>
		<category><![CDATA[Hope]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inflammation]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[Mayo]]></category>
		<category><![CDATA[Memory]]></category>
		<category><![CDATA[microglia]]></category>
		<category><![CDATA[MNT]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[plaque]]></category>
		<category><![CDATA[prevalence]]></category>
		<category><![CDATA[progression]]></category>
		<category><![CDATA[prowl]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Southhampton]]></category>
		<category><![CDATA[tangles]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tau]]></category>
		<category><![CDATA[thief]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UCLA]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[‘The Memory Thief’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7420</guid>
		<description><![CDATA[Over several decades, in fact, since its very inception, pharma R&#38;D has been playing a crucial role in alleviating diseases of various types &#8211; from severe acute infections, to a large variety of non-infectious chronic illnesses, including many dreaded diseases, &#8230; <a href="http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Affordable Healthcare: Synergize Resources Through PPP Models</title>
		<link>http://www.tapanray.in/for-affordable-healthcare-synergize-resources-through-ppp-models/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-affordable-healthcare-synergize-resources-through-ppp-models</link>
		<comments>http://www.tapanray.in/for-affordable-healthcare-synergize-resources-through-ppp-models/#comments</comments>
		<pubDate>Mon, 24 Feb 2014 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Central]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[consulting]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[NHM]]></category>
		<category><![CDATA[NRHM]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pocket]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resources]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[synergize]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UHC]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4702</guid>
		<description><![CDATA[According to a 2012 study of IMS Consulting, the key factor of significantly high &#8216;Out of Pocket (OOP)&#8217; expenditure on healthcare in India is that people are pushed into seeking costlier private care services due to imbalanced infrastructure of healthcare workers, &#8230; <a href="http://www.tapanray.in/for-affordable-healthcare-synergize-resources-through-ppp-models/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-affordable-healthcare-synergize-resources-through-ppp-models/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A global pharmaceutical iconoclast, who sees “Fortune” beyond the creamy top layers of the society … even at the bottom of the Pyramid</title>
		<link>http://www.tapanray.in/a-global-pharmaceutical-iconoclast-who-sees-fortune-beyond-the-creamy-top-layers-of-the-society-even-at-the-bottom-of-the-pyramid/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-global-pharmaceutical-iconoclast-who-sees-fortune-beyond-the-creamy-top-layers-of-the-society-even-at-the-bottom-of-the-pyramid</link>
		<comments>http://www.tapanray.in/a-global-pharmaceutical-iconoclast-who-sees-fortune-beyond-the-creamy-top-layers-of-the-society-even-at-the-bottom-of-the-pyramid/#comments</comments>
		<pubDate>Mon, 22 Mar 2010 00:30:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[at]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[bottom]]></category>
		<category><![CDATA[creamy]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Even]]></category>
		<category><![CDATA[Fortune]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[iconoclast]]></category>
		<category><![CDATA[layers]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pyramid]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sees]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=451</guid>
		<description><![CDATA[In March 2009 GlaxoSmithKline (GSK) unraveled a path breaking vision, within the global pharmaceutical industry, with the creation of a ‘voluntary patent pool’to spark development of new treatments for neglected diseases of the poorest countries of the world. The head &#8230; <a href="http://www.tapanray.in/a-global-pharmaceutical-iconoclast-who-sees-fortune-beyond-the-creamy-top-layers-of-the-society-even-at-the-bottom-of-the-pyramid/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-global-pharmaceutical-iconoclast-who-sees-fortune-beyond-the-creamy-top-layers-of-the-society-even-at-the-bottom-of-the-pyramid/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
